secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001558370-23-003169
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences reports 2022 net loss $18.1M, cash $5.9M, IND for PMN310 expected in 60 days
--------------------------------------------------------------------------------

- Net loss $18.1M in 2022 vs $9.8M in 2021; cash $5.9M vs $16.9M.
- R&D expenses rose to $16.1M from $4.6M, driven by PMN310 IND preparation.
- IND for Alzheimer's candidate PMN310 expected within 60 days; Phase 1a planned.
- Completed GLP toxicology for PMN310; no adverse effects at 5x planned highest dose.
- Discovery programs: PMN267 (ALS) and PMN442 (MSA) selected and humanized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023003169/0001558370-23-003169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023003169/pmn-20230308x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer